Pharmacogenetics of isoniazid-induced hepatotoxicity

References

• An HR, Wu XQ, Wang ZY, et al. (2012). NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients. Clin Exp Pharmacol Physiol 39:535–543
   PubMed Web of Science ®Google Scholar
• Anonymous. (2014). World TB day: Reach the 3 Million. Available from: http://www.who.int/campaigns/tb-day/2014/en/ [last accessed 3 May 2014]
   Google Scholar
• Babalik A, Arda H, Bakirci N, et al. (2012). Management of and risk factors related to hepatotoxicity during tuberculosis treatment. Tuberk Toraks 60:136–144
   PubMedGoogle Scholar
• Balamurugan A, Sharma SK, Mehra NK. (2004). Human leukocyte antigen class I supertypes influence susceptibility and severity of tuberculosis. J Infect Dis 189:805–811
   PubMed Web of Science ®Google Scholar
• Bhadauria S, Mishra R, Kanchan R, et al. (2010). Isoniazid-induced apoptosis in HepG2 cells: Generation of oxidative stress and Bcl-2 down-regulation. Toxicol Mech Methods 20:242–251
   PubMed Web of Science ®Google Scholar
• Bhadauria S, Singh G, Sinha N, Srivastava S. (2007). Isoniazid induces oxidative stress, mitochondrial dysfunction and apoptosis in Hep G2 cells. Cell Mol Biol (Noisy -le-grand) 53:102–114
   PubMed Web of Science ®Google Scholar
• Boelsterli UA, Lee KK. (2014). Mechanisms of isoniazid-induced idiosyncratic liver injury: Emerging role of mitochondrial stress. J Gastroenterol Hepatol 29:678–687
   PubMed Web of Science ®Google Scholar
• Brandon EF, Raap CD, Meijerman I, et al. (2003). An update on in vitro test methods in human hepatic drug biotransformation research: Pros and cons. Toxicol Appl Pharmacol 189:233–246
   PubMed Web of Science ®Google Scholar
• Cai Y, Yi J, Zhou C, Shen X. (2012). Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: A meta-analysis. PLoS One 7:e47769
   Google Scholar
• Chang JC, Liu EH, Lee CN, et al. (2012). UGT1A1 polymorphisms associated with risk of induced liver disorders by anti-tuberculosis medications. Int J Tuberc Lung Dis 16:376–378
   PubMed Web of Science ®Google Scholar
• Chowdhury A, Santra A, Bhattacharjee K, et al. (2006). Mitochondrial oxidative stress and permeability transition in isoniazid and rifampicin induced liver injury in mice. J Hepatol 45:117–126
   PubMed Web of Science ®Google Scholar
• Coomes MW, Prough RA. (1983). The mitochondrial metabolism of 1,2-disubstituted hydrazines, procarbazine and 1,2-dimethylhydrazine. Drug Metab Dispos 11:550–555
   PubMed Web of Science ®Google Scholar
• Du N, Sheng L, Liu Z, et al. (2013). The binding characteristics of isoniazid with copper – zinc superoxide dismutase and its effect on enzymatic activity. Chem Cent J 7:97
   PubMedGoogle Scholar
• Erikson JM, Prough RA. (1986). Oxidative metabolism of some hydrazine derivatives by rat liver and lung tissue fractions. J Biochem Toxicol 1:41–52
   PubMedGoogle Scholar
• Gupta VH, Amarapurkar DN, Singh M, et al. (2013). Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India. J Gastroenterol Hepatol 28:1368–1374
   PubMed Web of Science ®Google Scholar
• Huang YS. (2007). Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury. Expert Opin Drug Metab Toxicol 3:1–8
   PubMed Web of Science ®Google Scholar
• Huang YS. (2014). Recent progress in genetic variation and risk of antituberculosis drug-induced liver injury. J Chin Med Assoc 77:169–173
   PubMed Web of Science ®Google Scholar
• Huang YS, Chern HD, Su WJ, et al. (2003). Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 37:924–930
   PubMed Web of Science ®Google Scholar
• Huang YS, Su WJ, Huang YH, et al. (2007). Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H: Quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J Hepatol 47:128–134
   PubMed Web of Science ®Google Scholar
• Hussain Z, Kar P, Husain SA. (2003). Antituberculosis drug-induced hepatitis: Risk factors, prevention and management. Indian J Exp Biol 41:1226–1232
   PubMedGoogle Scholar
• Jaeschke H, Knight TR, Bajt ML. (2003). The role of oxidant stress and reactive nitrogen species in acetaminophen hepatotoxicity. Toxicol Lett 144:279–288
   PubMed Web of Science ®Google Scholar
• Lauterburg BH, Smith CV, Todd EL, Mitchell JR. (1985). Pharmacokinetics of the toxic hydrazino metabolites formed from isoniazid in humans. J Pharmacol Exp Ther 235:566–570
   PubMed Web of Science ®Google Scholar
• Lee SW, Chung LS, Huang HH, et al. (2010). NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. Int J Tuberc Lung Dis 14:622–626
   PubMed Web of Science ®Google Scholar
• Lee WM. (1995). Drug-induced hepatotoxicity. N Engl J Med 333:1118–1127
   PubMed Web of Science ®Google Scholar
• Li C, Long J, Hu X, Zhou Y. (2013). GSTM1 and GSTT1 genetic polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity: An updated meta-analysis. Eur J Clin Microbiol Infect Dis 32:859–868
   PubMed Web of Science ®Google Scholar
• Mahapatra S, Woolhiser LK, Lenaerts AJ, et al. (2012). A novel metabolite of antituberculosis therapy demonstrates host activation of isoniazid and formation of the isoniazid-NAD+ adduct. Antimicrob Agents Chemother 56:28–35
   PubMed Web of Science ®Google Scholar
• Metushi IG, Cai P, Zhu X, et al. (2011). A fresh look at the mechanism of isoniazid-induced hepatotoxicity. Clin Pharmacol Ther 89:911–914
   PubMed Web of Science ®Google Scholar
• Metushi IG, Sanders C, Lee WM, Uetrecht J. (2014). Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver failure. Hepatology 59:1084–1093
   PubMed Web of Science ®Google Scholar
• Moloney SJ, Guengerich FP, Prough RA. (1985). Propane and propylene formation during the microsomal metabolism of iproniazid and isopropylhydrazine. Life Sci 36:947–954
   PubMed Web of Science ®Google Scholar
• Nanashima K, Mawatari T, Tahara N, et al. (2012). Genetic variants in antioxidant pathway: Risk factors for hepatotoxicity in tuberculosis patients. Tuberculosis (Edinb) 92:253–259
   PubMed Web of Science ®Google Scholar
• Oyake T, Itoh K, Motohashi H, et al. (1996). Bach proteins belong to a novel family of BTB-basic leucine zipper transcription factors that interact with MafK and regulate transcription through the NF-E2 site. Mol Cell Biol 16:6083–6095
   PubMed Web of Science ®Google Scholar
• Peretti E, Karlaganis G, Lauterburg BH. (1987). Acetylation of acetylhydrazine, the toxic metabolite of isoniazid, in humans. Inhibition by concomitant administration of isoniazid. J Pharmacol Exp Ther 243:686–689
   PubMed Web of Science ®Google Scholar
• Prough RA, Wittkop JA, Reed DJ. (1969). Evidence for the hepatic metabolism of some monoalkylhydrazines. Arch Biochem Biophys 131:369–373
   PubMed Web of Science ®Google Scholar
• Roy PD, Majumder M, Roy B. (2008). Pharmacogenomics of anti-TB drugs-related hepatotoxicity. Pharmacogenomics 9:311–321
   PubMed Web of Science ®Google Scholar
• Sharma SK, Balamurugan A, Saha PK, et al. (2002). Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 166:916–919
   PubMed Web of Science ®Google Scholar
• Singla N, Gupta D, Birbian N, Singh J. (2014). Association of NAT2, GST and CYP2E1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity. Tuberculosis (Edinb) 94:293–298
   PubMed Web of Science ®Google Scholar
• Sotgiu G, Migliori GB. (2014). Facing multi-drug resistant tuberculosis. Pulm Pharmacol Ther [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Spearman ME, Moloney SJ, Prough RA. (1984). Effect of cytosolic components on the metabolism of the hydrazide iproniazid. Mol Pharmacol 26:566–573
   PubMed Web of Science ®Google Scholar
• Steele MA, Burk RF, DesPrez RM. (1991). Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 99:465–471
   PubMed Web of Science ®Google Scholar
• Strange RC, Spiteri MA, Ramachandran S, Fryer AA. (2001). Glutathione-S-transferase family of enzymes. Mutat Res 482:21–26
   PubMed Web of Science ®Google Scholar
• Teixeira RL, Miranda AB, Pacheco AG, et al. (2007). Genetic profile of the arylamine N-acetyltransferase 2 coding gene among individuals from two different regions of Brazil. Mutat Res 624:31–40
   PubMed Web of Science ®Google Scholar
• Timbrell JA, Mitchell JR, Snodgrass WR, Nelson SD. (1980). Isoniazid hepatoxicity: The relationship between covalent binding and metabolism in vivo. J Pharmacol Exp Ther 213:364–369
   PubMed Web of Science ®Google Scholar
• Timperio AM, Rinalducci S, Zolla L. (2005). Hydrazide derivatives produce active oxygen species as hydrazine. Bioorg Chem 33:459–469
   PubMed Web of Science ®Google Scholar
• Wada M. (2001). Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients. Kekkaku 76:33–43
   PubMedGoogle Scholar
• Wiebkin P, Sieg MS, Nelson RE, et al. (1982). Inhibition of metabolism-mediated cytotoxicity by 1,1-disubstituted hydrazines in mouse mastocytoma (line P815) cells. Biochem Pharmacol 31:2921–2928
   PubMed Web of Science ®Google Scholar
• Xiang Y, Ma L, Wu W, et al. (2014). The incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1. PLoS One 9:e85905
   PubMedGoogle Scholar
• Yamamoto T, Suou T, Hirayama C. (1986). Elevated serum aminotransferase induced by isoniazid in relation to isoniazid acetylator phenotype. Hepatology 6:295–298
   PubMed Web of Science ®Google Scholar
• Zang Y, Zhao S, Doll MA, et al. (2007). Functional characterization of the A411T (L137F) and G364A (D122N) genetic polymorphisms in human N-acetyltransferase 2. Pharmacogenet Genomics 17:37–45
   PubMed Web of Science ®Google Scholar
• Zucker SD, Qin X, Rouster SD, et al. (2001). Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci USA 98:12671–12676
   PubMed Web of Science ®Google Scholar